Merck news

The new center will focus on antibody and mRNA research, supporting 550 employees by 2027. It aims for near carbon-neutral operations and gold certification from the German Sustainable Building Council.

The investment will boost single-use assembly production, create 800 jobs by 2028, and support growth in novel therapies and vaccines, aligning with sustainability goals and global expansion plans.

Over 100 new jobs will be created as a new facility for next-gen oncology biologics begins construction, operational by 2025, adding to the existing 530 staff and 700 construction roles.

The investment will boost membrane and filtration manufacturing, create 370 jobs by 2027, and support novel therapies, vaccines, and diagnostics, aligning with sustainability goals.

€150M investment in Aubonne, Switzerland, for new building with advanced tech to boost production of biotech medicines, meeting global demand. Completion expected by 2023.